Research programme: anti-microbial therapeutics - Assembly Biosciences

Drug Profile

Research programme: anti-microbial therapeutics - Assembly Biosciences

Alternative Names: AB M102; AB M103; ABI M201; ABI M301; ABI-M101; ABM-101; Gemicel based therapeutics - Ventrus Biosciences; Gemicel based therapeutics -Assembly Biosciences; Microbiome therapeutics - Assembly Biosciences

Latest Information Update: 06 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Assembly Biosciences
  • Class Antibacterials; Bacteria; Irritable bowel syndrome therapies; Proteins; Small molecules; Viruses
  • Mechanism of Action Bacterial toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Clostridium-difficile-infections
  • Research Crohn's disease; Irritable bowel syndrome; Ulcerative colitis

Most Recent Events

  • 05 Feb 2018 Assembly Biosciences has patent pending for Gemicel® capsule oral delivery system
  • 21 Feb 2017 Assembly Biosciences receives early termination of the waiting period required by the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for licensing agreement with Allergan
  • 09 Jan 2017 ABI M201, ABI M301 and two compounds for Ulcerative colitis, Crohn's disease and Irritable bowel syndrome licensed to Allergan in World
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top